Pretraga

Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1263180

Anthracyclines in the treatment of early breast cancer friend or foe?

Vuger, Ana Tecic; Tiscoski, Katsuki; Apolinario, Thiago; Cardoso, Fatima
Anthracyclines in the treatment of early breast cancer friend or foe? // The Breast, 65 (2022), 67-76 doi:10.1016/j.breast.2022.06.007 (međunarodna recenzija, članak, znanstveni)

CROSBI ID: 1263180 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Anthracyclines in the treatment of early breast cancer friend or foe?

Autori
Vuger, Ana Tecic ; Tiscoski, Katsuki ; Apolinario, Thiago ; Cardoso, Fatima

Izvornik
The Breast (0960-9776) 65 (2022); 67-76

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Anthracyclines ; Early breast cancer ; Efficacy ; Toxicity ; Treatment.

Sažetak
Standard chemotherapy for early breast cancer consists generally of an anthracycline - taxane - based regimen, preferably in sequence. Anthracyclines are among the most active cytotoxic drugs against breast cancer. Nevertheless, benefits attained by the use of the more potent anthracycline schedules must be balanced against increased short - and long - term toxicity, and treatment options must be individualized for each patient. Authors review available data regarding anthracycline efficacy and toxicity in the early breast cancer setting and the potential directions for future research

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA

Ustanove:
Klinika za tumore

Poveznice na cjeloviti tekst rada:

doi

Citiraj ovu publikaciju:

Vuger, Ana Tecic; Tiscoski, Katsuki; Apolinario, Thiago; Cardoso, Fatima
Anthracyclines in the treatment of early breast cancer friend or foe? // The Breast, 65 (2022), 67-76 doi:10.1016/j.breast.2022.06.007 (međunarodna recenzija, članak, znanstveni)
Vuger, A., Tiscoski, K., Apolinario, T. & Cardoso, F. (2022) Anthracyclines in the treatment of early breast cancer friend or foe?. The Breast, 65, 67-76 doi:10.1016/j.breast.2022.06.007.
@article{article, author = {Vuger, Ana Tecic and Tiscoski, Katsuki and Apolinario, Thiago and Cardoso, Fatima}, year = {2022}, pages = {67-76}, DOI = {10.1016/j.breast.2022.06.007}, keywords = {Anthracyclines, Early breast cancer, Efficacy, Toxicity, Treatment.}, journal = {The Breast}, doi = {10.1016/j.breast.2022.06.007}, volume = {65}, issn = {0960-9776}, title = {Anthracyclines in the treatment of early breast cancer friend or foe?}, keyword = {Anthracyclines, Early breast cancer, Efficacy, Toxicity, Treatment.} }
@article{article, author = {Vuger, Ana Tecic and Tiscoski, Katsuki and Apolinario, Thiago and Cardoso, Fatima}, year = {2022}, pages = {67-76}, DOI = {10.1016/j.breast.2022.06.007}, keywords = {Anthracyclines, Early breast cancer, Efficacy, Toxicity, Treatment.}, journal = {The Breast}, doi = {10.1016/j.breast.2022.06.007}, volume = {65}, issn = {0960-9776}, title = {Anthracyclines in the treatment of early breast cancer friend or foe?}, keyword = {Anthracyclines, Early breast cancer, Efficacy, Toxicity, Treatment.} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE

Citati:

    Altmetrijski pokazatelji:


    Podijeli:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font
    CROSBI koristi kolačiće (cookies) kako bi poboljšao funkcionalnost stranice.